Home » Stocks » OGEN

Oragenics Inc. (OGEN)

Stock Price: $0.711 USD 0.014 (2.02%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Pre-market: $0.700 -0.011 (-1.49%) Apr 19, 4:28 AM
Market Cap 77.91M
Revenue (ttm) n/a
Net Income (ttm) -26.43M
Shares Out 56.53M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $0.711
Previous Close $0.697
Change ($) 0.014
Change (%) 2.02%
Day's Open 0.670
Day's Range 0.630 - 0.727
Day's Volume 4,173,684
52-Week Range 0.372 - 2.090

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Pre-market movers this morning include some high-profile top gainers and losers. Take a look at this list that includes NFT stocks and EV plays.

Other stocks mentioned: APOP, CIDM, CNET, CSCW, ENOB, NGA, SGOC ...
3 weeks ago - InvestorPlace

Oragenics Inc (NYSE: OGEN) stock is soaring higher after announcing a deal related to its Terra CoV-2 vaccine candidate against COVID-19. Oragenics has reached an agreement with Biodextris that will all...

1 month ago - Benzinga

Oragenics (OGEN) stock is soaring higher on Tuesday after announcing a deal concerning its vaccine candidate for the novel coronavirus. The post OGEN Stock: Why Shares of Biotech Oragenics Are Skyrocket...

1 month ago - InvestorPlace

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine

1 month ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics to Participate in Two Investment Conferences During March

1 month ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

2 months ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice

2 months ago - Business Wire

Oragenics (OGEN) stock is soaring higher on Thursday from new coronavirus vaccine news after just receiving a boost last week. The post OGEN Stock Alert: Why Oragenics Shares Are Flying Again Thursday a...

3 months ago - InvestorPlace

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Issues Letter to Stockholders

3 months ago - Business Wire

Oragenics (OGEN) is seeing shares of OGEN stock take off on Thursday on a news update for its vaccine to treat the novel coronavirus. The post OGEN Stock Alert: 14 Things to Know About Oragenics as Shar...

3 months ago - InvestorPlace

TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS ENTERS INTO MATERIAL TRANSFER AGREEMENT WITH ADJUVANCE TECHNOLOGIES FOR COVID-19 VACCINE ADJUVANT

3 months ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS ANNOUNCES CLOSING OF $6.5 MILLION REGISTERED DIRECT OFFERING

3 months ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. Announces $6.5 Million Registered Direct Offering

3 months ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Closing of $6.0 Million Underwritten Public Offering

4 months ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS PRICES $5.25 MILLION COMMON STOCK OFFERING

4 months ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Proposed Underwritten Public Offering

4 months ago - Business Wire

Oragenics is planning to launch clinical trials of its coronavirus vaccine in early 2021. OGEN stock is soaring on the news.

6 months ago - InvestorPlace

TAMPA, Fla.--(BUSINESS WIRE)--FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine

6 months ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine

6 months ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Inc.

7 months ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies

8 months ago - Business Wire

About OGEN

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The compan... [Read more...]

Industry
Biotechnology
Founded
1996
Stock Exchange
NYSEAMERICAN
Ticker Symbol
OGEN
Full Company Profile

Financial Performance

Financial Statements